13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001534261
Total reported value
$2.0B
$2.0B
35 檔
41.3%
According to the latest 13F quarterly dataset, Casdin Capital, LLC managed an equity portfolio of $2.0B at the end of Q3 2024, spanning 35 distinct U.S. exchange-listed positions.
Casdin Capital, LLC executed strategic sector rebalancing during Q3 2024, establishing 1 new positions while fully exiting 4 holdings and trimming 6 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BLFS | Biolife Solutions Inc | Stock-Other | 14.54% | -2.03% | — | |
| 2 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 12.44% | +5.18% | -6.64% | |
| 3 | WGS | Genedx Holdings CORP | Stock-Other | 9.92% | -1.88% | -0.55% | |
| 4 | LAB | Standard Biotools Inc | Stock-Other | 9.17% | -2.52% | +11.41% | |
| 5 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 8.94% | +0.42% | NEW | |
| 6 | ILMN | Illumina Inc | Stock-Healthcare | 6.52% | -0.29% | +56.25% | |
| 7 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 6.38% | — | — | |
| 8 | RLAY | Relay Therapeutics Inc | Stock-Other | 4.37% | +4.16% | +9.50% | |
| 9 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.12% | -0.75% | — | |
| 10 | EXK | Exact Sciences CORP | Stock-Materials | 2.95% | — | — | |
| 11 | NTLA | Intellia Therapeutics Inc | Stock-Other | 2.74% | -0.04% | — | |
| 12 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.05% | -1.13% | — | |
| 13 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.01% | — | — | |
| 14 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.92% | -0.05% | -23.85% | |
| 15 | CDXS | Codexis Inc | Stock-Other | 1.66% | — | +305.00% | |
| 16 | VCYT | Veracyte Inc | Stock-Other | 1.51% | +0.14% | -22.33% | |
| 17 | NGNE | Neurogene Inc | Stock-Other | 1.47% | +0.26% | — | |
| 18 | ✓ | Verve Therapeutics Inc | Stock-Other | 1.29% | — | +30.61% | |
| 19 | BEAM | Beam Therapeutics Inc | Stock-Other | 1.27% | -0.12% | +14.81% | |
| 20 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.87% | -0.01% | — | |
| 21 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.83% | — | +43.75% | |
| 22 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.63% | — | — | |
| 23 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.61% | — | — | |
| 24 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.61% | — | +216.67% | |
| 25 | GH | Guardant Health Inc | Stock-Healthcare | 0.54% | -0.81% | +250.00% | |
| 26 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.38% | -0.03% | — | |
| 27 | IPSC | Century Therapeutics Inc | Stock-Other | 0.37% | -0.06% | -38.11% | |
| 28 | GRAL | Grail Inc | Stock-Healthcare | 0.32% | +0.74% | +337.51% | |
| 29 | ABSI | Absci CORP | Stock-Other | 0.25% | +0.34% | — | |
| 30 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.12% | -0.01% | — | |
| 31 | PRME | Prime Medicine Inc | Stock-Other | 0.09% | -0.25% | — | |
| 32 | EXAIEUR | Exscientia PLC | Stock-Other | 0.07% | — | — | |
| 33 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.03% | — | -67.05% | |
| 34 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 0.02% | — | — | |
| 35 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | WGS | Genedx Holdings CORP | +2.9% | -0.55% | Trim |
| 2 | ILMN | Illumina Inc | +2.7% | +56.25% | Add |
| 3 | CDXS | Codexis Inc | +1.2% | +305.00% | Add |
| 4 | EXK | Exact Sciences CORP | +0.9% | — | Unchanged |
| 5 | LAB | Standard Biotools Inc | +0.5% | +11.41% | Add |
| 6 | SNDX | Syndax Pharmaceuticals Inc | +0.4% | +216.67% | Add |
| 7 | GH | Guardant Health Inc | +0.3% | +250.00% | Add |
| 8 | BLFS | Biolife Solutions Inc | +0.3% | — | Unchanged |
| 9 | GRAL | Grail Inc | +0.2% | +337.51% | Add |
| 10 | RLAY | Relay Therapeutics Inc | +0.2% | +9.50% | Add |
| 11 | ✓ | Verve Therapeutics Inc | +0.2% | +30.61% | Add |
| 12 | VCYT | Veracyte Inc | +0.1% | -22.33% | Trim |
| 13 | BEAM | Beam Therapeutics Inc | +0.1% | +14.81% | Add |
| 14 | TSVT* | 2seventy Bio Inc | 0% | — | Unchanged |
| 15 | ABSI | Absci CORP | 0% | — | Unchanged |
| 16 | DNA | Ginkgo Bioworks Holdings Inc | 0% | NEW | New buy |
| 17 | NGNE | Neurogene Inc | 0% | — | Unchanged |
| 18 | PACB | Pacific Biosciences Of Calif | 0% | — | Unchanged |
| 19 | KRON1USD | Kronos Bio Inc | — | — | Unchanged |
| 20 | EXAIEUR | Exscientia PLC | 0% | — | Unchanged |
| 21 | CTNM | Contineum Therapeutics Inc-a | 0% | — | Unchanged |
| 22 | ALNY | Alnylam Pharmaceuticals Inc | 0% | — | Unchanged |
| 23 | ✓ | 0% | EXIT | Sold out | |
| 24 | GLUE | Monte Rosa Therapeutics Inc | 0% | -67.05% | Trim |
| 25 | DNA4EUR | Ginkgo Bioworks Holdings Inc | 0% | EXIT | Sold out |
| 26 | GPCR | Structure Therapeutics Inc | -0.1% | — | Unchanged |
| 27 | PRME | Prime Medicine Inc | -0.1% | — | Unchanged |
| 28 | RNAGBP | Avidity Biosciences Inc | -0.1% | — | Unchanged |
| 29 | TNGX | Tango Therapeutics Inc | -0.2% | — | Unchanged |
| 30 | KYTX | Kyverna Therapeutics Inc | -0.3% | EXIT | Sold out |
| 31 | DNLI | Denali Therapeutics Inc | -0.4% | -23.85% | Trim |
| 32 | FDMT | 4d Molecular Therapeutics In | -0.5% | +43.75% | Add |
| 33 | RVMD | Revolution Medicines Inc | -0.6% | -6.64% | Trim |
| 34 | IPSC | Century Therapeutics Inc | -0.6% | -38.11% | Trim |
| 35 | 2655787D | Blueprint Medicines CORP | -0.7% | — | Unchanged |
| 36 | NTLA | Intellia Therapeutics Inc | -0.7% | — | Unchanged |
| 37 | TNYA | Tenaya Therapeutics Inc | -0.7% | — | Unchanged |
| 38 | PLRX | Pliant Therapeutics Inc | -0.8% | EXIT | Sold out |
| 39 | SRPT | Sarepta Therapeutics Inc | -4% | — | Unchanged |
According to official SEC Form 13F filings, Casdin Capital, LLC reported a total U.S. public equity portfolio value of $2.0B across 35 disclosed positions in Q3 2024.
During Q3 2024, Casdin Capital, LLC's top holdings by market value included BLFS (14.5%)、RVMD (12.4%)、WGS (9.9%). The largest single position, BLFS, represented 14.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BLFS, RVMD, WGS) accounted for 41.3% of total reported equity market value during Q3 2024.
Top New Position Initiated
DNA
市值: $297.4K
Top Position Liquidated / Trimmed
PLRX
前期市值: $10.8M
In Q3 2024, Casdin Capital, LLC made 21 total portfolio adjustments, initiating 1 new buys, adding to 10 positions, trimming 6 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.